# US 2013/0158059 A1 · Nilotinib salts and crystalline forms thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158059 A1
- Document ID: US20130158059A1
- Status: Published application
- Kind: A1
- Application number: 13/806,069
- Filed: 2011-06-21
- Published: 2013-06-20
- Earliest claimed: 2010-06-21
- Assignees: Teva Pharmaceutical Industries Ltd.
- Inventors: Maytal Piran; Jacob Rendell
- Web page: https://patentgrep.com/patent/US20130158059A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61K 31/506: not condensed and containing further heterocyclic rings
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07C 53/126: Acids containing more than four carbon atoms
- C07C 55/07: Salts thereof
- C07C 55/08: Malonic acid
- C07C 55/12: Glutaric acid
- C07C 55/14: Adipic acid
- C07C 55/22: Tricarboxylic acids
- C07C 57/15: Fumaric acid
- C07C 59/48: containing six-membered aromatic rings
- C07C 62/02: Saturated compounds containing hydroxy or O-metal groups
- C07C 229/24: having more than one carboxyl group bound to the carbon skeleton, e.g. aspartic acid
- C07C 309/25: having sulfo groups bound to carbon atoms of rings other than six-membered aromatic rings of a carbon skeleton
- C07C 309/30: of six-membered aromatic rings substituted by alkyl groups
- A61K 31/4178: not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

Nilotinib salts and crystalline forms thereof have been prepared and characterized.

## Claims

### Claim 1

A Crystalline Form of Nilotinib L-tartrate selected from:
a) Crystalline Form I of Nilotinib L-tartrate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 9.4, 11.7, 12.7, 18.2 and 19.0 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 14, and combinations thereof;
b) Crystalline Form II of Nilotinib L-tartrate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.7, 15.7, 17.2, 19.4 and 20.0 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 15; and combinations thereof;
c) Crystalline Form III of Nilotinib L-tartrate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.2, 9.1, 12.3, 15.0 and 17.6 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 16; and combinations thereof;
d) Crystalline Form IV of Nilotinib L-tartrate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 13.6, 18.3, 19.5, 21.9 and 24.3 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 60; and combinations thereof;
e) Crystalline Form V of Nilotinib L-tartrate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.6, 7.6, 14.1, 17.8 and 19.5 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 61; and combinations thereof; and
f) Crystalline Form VI of Nilotinib L-tartrate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.7, 12.1, 16.3, 21.0 and 24.4 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 62; and combinations thereof.

### Claim 2 (depends on 1)

Crystalline Form IV of Nilotinib L-tartrate according to claim 1, characterized by an X-ray powder diffraction pattern having peaks at 13.6 18.3, 19.5, 21.9 and 24.3 degrees two theta±0.2 degrees two theta.

### Claim 3 (depends on 2)

The crystalline Nilotinib L-tartrate according to claim 2, further characterized by data selected from: a solid state 13C NMR spectrum having signals at 118.7, 136.2 and 172.7±0.2 ppm; a solid-state 13C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift in the chemical shift range of 100 to 180 ppm and another in the chemical shift range of 100 to 180 ppm of 12.0, 29.5 and 66.0±0.1 ppm; a solid state 13C NMR spectrum as depicted in any one of FIGS. 71-72; and combinations thereof.

### Claim 4 (depends on 2)

The crystalline Nilotinib L-tartrate according to claim 2, further characterized by an X-ray powder diffraction pattern having any one, two, three, four or five additional peaks selected from peaks at 10.6, 11.3, 20.8, 22.9 and 25.0 degrees two theta±0.2 degrees two theta □

### Claim 5 (depends on 2)

The crystalline Nilotinib L-tartrate according to claim 2, wherein the crystalline form is anhydrous.

### Claim 6 (depends on 2)

The crystalline Nilotinib L-tartrate according to claim 2, wherein the crystalline form is of Nilotinib mono L-tartrate salt.

### Claim 7

(canceled)

### Claim 8

(canceled)

### Claim 9

A crystalline form of Nilotinib hydrobromide selected from:
a) Nilotinib hydrobromide form I, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.8, 6.8, 9.0, 9.6 and 13.6 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 51, and combinations thereof;
b) Nilotinib hydrobromide form II, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 17.3, 21.5, 24.5 and 26.5 degrees two theta±0.2 degrees two theta and a broad peak having a maximum at 20.8 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 52, and combinations thereof;
c) Nilotinib hydrobromide form III, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.5, 8.5, 12.3, 19.5 and 20.6 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 53, and combinations thereof;
d) Nilotinib hydrobromide form IV, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.7, 9.3, 11.3, 14.0 and 20.2 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 54, and combinations thereof;
e) Nilotinib hydrobromide form V, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 7.4, 9.4, 12.0, 14.8 and 16.0 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 55, and combinations thereof;
f) Nilotinib hydrobromide form VI, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 2.9, 11.8, 12.8, 18.4 and 22.3 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 56, and combinations thereof;
g) Nilotinib hydrobromide form VII, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.1, 12.2, 13.8, 16.3 and 23.3 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 58, and combinations thereof;
h) Nilotinib hydrobromide form VIII, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.5, 17.0, 19.2, 20.6 and 21.8 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 64, and combinations thereof;
i) Nilotinib hydrobromide form IX, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 16.9, 18.7, 20.9, 21.8 and 26.7 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 65, and combinations thereof;
j) Nilotinib hydrobromide form X, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 8.8, 15.5, 18.6, 22.2 and 24.2 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 66, and combinations thereof; and
k) Nilotinib hydrobromide form XI, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 7.1, 14.1, 18.6, 21.9 and 22.5 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 67, a solid state 13C NMR spectrum having signals at 129.8, 132.3 and 160.5±0.2 ppm, a solid-state 13C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift in the chemical shift range of 100 to 180 ppm and another in the chemical shift range of 100 to 180 ppm of 23.0, 25.5 and 53.7±0.1 ppm, a solid state 13C NMR spectrum as depicted in any one of FIGS. 73-74, and combinations thereof.

### Claim 10 (depends on 9)

The crystalline form XI of Nilotinib hydrobromide according to claim 9, characterized by an X-ray powder diffraction pattern having peaks at 7.1, 14.1, 18.6, 21.9 and 22.5 degrees two theta±0.2 degrees two theta.

### Claim 11 (depends on 10)

The crystalline form XI of Nilotinib hydrobromide according to claim 10, further characterized by X-ray powder diffraction pattern having any one, two, three, four or five peaks selected from peaks at 9.0, 11.1, 13.8, 15.2 and 19.7 degrees two theta±0.2 degrees two theta.

### Claim 12 (depends on 9)

The Nilotinib hydrobromide crystalline form according to claim 9, wherein the crystalline form is of Nilotinib monohydrobromide salt.

### Claim 13

(canceled)

### Claim 14

A crystalline form of Nilotinib succinate selected from:
a) Nilotinib succinate Form I, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.5, 7.6, 11.3, 17.4 and 18.7 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern having peaks at 4.4, 7.6, 11.3, 17.3 and 18.7 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 10, and combinations thereof;
b) Nilotinib succinate form II, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.8, 9.5, 13.3, 19.2 and 21.0 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 11, and combinations thereof; and
c) Nilotinib succinate form III, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.8, 9.0, 10.4, 15.3 and 19.4 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 12, and combinations thereof.

### Claim 15

Crystalline form I of Nilotinib glutamate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.5, 5.5, 7.5, 9.0 and 18.0 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 24; and combinations thereof.

### Claim 16

A crystalline form of Nilotinib acetate selected from:
a) Nilotinib acetate form I, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 5.4, 7.6, 8.8 degrees two theta±0.2 degrees two theta and broad peaks having maxima at 18.4 and 24.5 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 37, and combinations thereof;
b) Nilotinib acetate form II, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 7.2, 7.8, 8.6, 10.9 and 13.6 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 38, and combinations thereof;
c) Nilotinib acetate form III, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 3.6, 6.7, 10.0, 15.8 and 21.2 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 39, and combinations thereof;
d) Nilotinib acetate form IV, characterized by by data selected from: an X-ray powder diffraction pattern having peaks at 4.7, 7.1, 9.5 and 14.9 degrees two theta±0.2 degrees two theta and a broad peak having a maximum at 14.1 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 40, and combinations thereof;
e) Nilotinib acetate form V, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 7.4, 11.3, 14.2, 14.9 and 19.1 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 41, and combinations thereof; and
f) Nilotinib acetate form VI, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 6.4, 10.8, 17.7, 19.0 and 19.7 degrees two theta±0.2 degrees two theta, an X-ray powder diffraction pattern substantially as depicted in FIG. 42, and combinations thereof.

### Claim 17

A crystalline form of Nilotinib L-malate, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 4.5, 7.5, 9.3, 11.2 and 15.2 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 43; and combinations thereof.

### Claim 18 (depends on 1, 9, 14, 15, 16, 17)

A Nilotinib solid state form according to any one of claims 1, 9, 14-17, and 26 for use as a medicament, preferably for the treatment of drug-resistant chronic myelogenous leukemia (CML).

### Claim 19 (depends on 1, 9, 14, 15, 16, 17)

A pharmaceutical composition comprising the Nilotinib solid state form according to any one of claims 1, 9, 14-17, and 26, and at least one pharmaceutically acceptable excipient.

### Claim 20 (depends on 19)

A method of treating a patient suffering from drug-resistant chronic myelogenous leukemia (CML), comprising administering to said patient an effective amount of the pharmaceutical composition according to claim 19.

### Claim 21 (depends on 1, 9, 14, 15, 16, 17)

A process for preparing Nilotinib HCl comprising preparing a Nilotinib solid state form according to any one of claims 1, 9, 14-17, and 26, and converting said Nilotinib salt or solid state form to Nilotinib HCl.

### Claim 22 (depends on 21)

A process according to claim 21, wherein the converting step comprises:
a. reacting the Nilotinib solid state form with HCl; or
b. reacting the Nilotinib solid state form with a base to obtain a Nilotinib base; and reacting the Nilotinib base with HCl.

### Claim 23

(canceled)

### Claim 24 (depends on 1, 9, 14, 15, 16, 17)

A process for preparing Nilotinib base comprising preparing a Nilotinib solid state form according to any one of claims 1, 9, 14-17, and 26, and converting said salt or solid state form to Nilotinib base.

### Claim 25

(canceled)

### Claim 26

A crystalline form of Nilotinib maleate selected from:
a) Nilotinib maleate Form I, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 7.5, 11.1, 15.3, 16.9 and 18.6 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 32; and combinations thereof;
b) Nilotinib maleate Form II, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 5.2, 10.4, 15.6, 21.0 and 25.6 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 33; and combinations thereof;
c) Nilotinib maleate Form III, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 7.4, 10.4, 14.9, 16.1 and 18.4 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 34; and combinations thereof;
d) Nilotinib maleate Form IV, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 5.6, 8.3, 10.1, 14.8 and 17.0 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 36; and combinations thereof; and
e) Nilotinib maleate Form V, characterized by data selected from: an X-ray powder diffraction pattern having peaks at 9.7, 13.5, 16.6, 20.3 and 21.8 degrees two theta±0.2 degrees two theta; an X-ray powder diffraction pattern substantially as depicted in FIG. 57; and combinations thereof.

### Claim 27 (depends on 26)

Crystalline Form IV of Nilotinib maleate according to claim 26, characterized by an X-ray powder diffraction pattern having peaks at 5.6, 8.3, 10.1, 14.8 and 17.0 degrees two theta±0.2 degrees two theta.

### Claim 28 (depends on 27)

Crystalline Form IV of Nilotinib maleate according to claim 27, further characterized by additional X-ray powder diffraction peaks at 12.1, 17.7, 18.7, 22.7 and 24.3 degrees two theta±0.2 degrees two theta.

### Claim 29 (depends on 26)

Crystalline Form V of Nilotinib maleate according to claim 26, characterized by an X-ray powder diffraction pattern having peaks at 9.7, 13.5, 16.6, 20.3 and 21.8 degrees two theta±0.2 degrees two theta.

### Claim 30 (depends on 29)

Crystalline Form V of Nilotinib maleate according to claim 29, further characterized by additional X-ray powder diffraction peaks at 10.6, 11.2, 14.5, 17.4 and 18.4 degrees two theta±0.2 degrees two theta.

### Claim 31 (depends on 1)

Crystalline Form VI of Nilotinib L-tartrate according to claim 1, characterized by an X-ray powder diffraction pattern having peaks at 4.7, 12.1, 16.3, 21.0 and 24.4 degrees two theta±0.2 degrees two theta.

### Claim 32 (depends on 31)

The crystalline Nilotinib L-tartrate Form VI according to claim 31, further characterized by data selected from: additional X-ray powder diffraction peaks at 8.1, 10.5, 13.5, 18.9 and 27.9 degrees two theta±0.2 degrees two theta; a solid state 13C NMR spectrum having signals at 118.7, 136.2 and 172.7±0.2 ppm; a solid-state 13C NMR spectrum having chemical shift differences between the signal exhibiting the lowest chemical shift in the chemical shift range of 100 to 180 ppm and another in the chemical shift range of 100 to 180 ppm of 12.0, 29.5 and 66.0±0.1 ppm; a solid state 13C NMR spectrum as depicted in any one of FIGS. 71-72; and combinations thereof.

### Claim 33 (depends on 31)

The crystalline Nilotinib L-tartrate Form VI according to claim 31, wherein the crystalline form is anhydrous.

### Claim 34 (depends on 31)

The crystalline Nilotinib L-tartrate Form VI according to claim 31, wherein the crystalline form is of Nilotinib mono L-tartrate salt.
